Dive into the Latest Financial Snapshot of 10x Genomics, Inc. (TXG)
The company's upcoming earnings report on Wednesday, May 6th is anticipated to show a consensus estimate EPS of -0.27.
Today, 10x Genomics, Inc. (TXG) is priced at $21.34, indicating a price change of -93.75 cents (-4.21%) from the previous close. With a trading volume of $564,364, the asset's performance is under scrutiny.
In the latest quarterly earnings reported on Wednesday, February 11th, the company posted an earnings per share of -0.13, surpassing the consensus estimate EPS of -0.19.
The company shows a positive cash flow with free cash flow amounting to $39 million and a net change in cash of $41.26 million.
Revealing a gross profit of $113 million and a net income of -$16.25 million, the company's revenue stands at $166 million, indicating a challenging operational scenario.
Key ratios depict varying performance metrics; notable ratios include a quick ratio of 4.09 and a net profit margin of -9.79%.
10x Genomics, Inc. exhibits robust financial health with $473.97 million in cash and cash equivalents and total assets amounting to $1 billion.
This comprehensive financial report sheds light on the current financial standing and future prospects of 10x Genomics, Inc. (TXG).
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.